Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 4719 entries
Sorted by: Best Match Show Resources per page
Unusual occurrence of rare lipid-rich carcinoma and conventional invasive ductal carcinoma in the one breast: case report.

Case reports in pathology

Machalekova K, Kajo K, Bencat M.
PMID: 23050179
Case Rep Pathol. 2012;2012:387045. doi: 10.1155/2012/387045. Epub 2012 Sep 20.

A 56-year-old woman noticed a palpable mass in her left breast during self-examination. Patient was admitted to our hospital and malignant bifocal tumour was diagnosed by ultrasonography, digital mammography, magnetic resonance, and core-cut biopsy. The patient underwent planned conservative...

Cite
Machalekova K, Kajo K, Bencat M. Unusual occurrence of rare lipid-rich carcinoma and conventional invasive ductal carcinoma in the one breast: case report. Case Rep Pathol. 2012;2012:387045doi: 10.1155/2012/387045.
Machalekova, K., Kajo, K., & Bencat, M. (2012). Unusual occurrence of rare lipid-rich carcinoma and conventional invasive ductal carcinoma in the one breast: case report. Case reports in pathology, 2012387045. https://doi.org/10.1155/2012/387045
Machalekova, Katarina, et al. "Unusual occurrence of rare lipid-rich carcinoma and conventional invasive ductal carcinoma in the one breast: case report." Case reports in pathology vol. 2012 (2012): 387045. doi: https://doi.org/10.1155/2012/387045
Machalekova K, Kajo K, Bencat M. Unusual occurrence of rare lipid-rich carcinoma and conventional invasive ductal carcinoma in the one breast: case report. Case Rep Pathol. 2012;2012:387045. doi: 10.1155/2012/387045. Epub 2012 Sep 20. PMID: 23050179; PMCID: PMC3461286.
Copy Download .nbib Format: NLM
Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.

OncoTargets and therapy

Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K.
PMID: 24124381
Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013.

Bevacizumab when combined with chemotherapy exerts significant activity against many solid tumors through tumor angiogenesis inhibition; however, it can induce severe side effects. We report the rare case of a 27-year-old premenopausal woman with locally advanced breast cancer that...

Cite
Ono M, Ito T, Kanai T, et al. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013;6:1393-8doi: 10.2147/OTT.S51164.
Ono, M., Ito, T., Kanai, T., Murayama, K., Koyama, H., Maeno, K., Mochizuki, Y., Iesato, A., Hanamura, T., Okada, T., Watanabe, T., & Ito, K. (2013). Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. OncoTargets and therapy, 61393-8. https://doi.org/10.2147/OTT.S51164
Ono, Mayu, et al. "Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer." OncoTargets and therapy vol. 6 (2013): 1393-8. doi: https://doi.org/10.2147/OTT.S51164
Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013. PMID: 24124381; PMCID: PMC3794845.
Copy Download .nbib Format: NLM
Quasi-Complete Response of Classic Kaposi's Sarcoma Treated with Weekly Paclitaxel.

Case reports in oncological medicine

Benbrahim Z, Arifi S, Benhammane H, Inani K, Gallouj S, Meziane M, Mernissi FZ, Mellas N, El Mesbahi O.
PMID: 23476845
Case Rep Oncol Med. 2013;2013:196878. doi: 10.1155/2013/196878. Epub 2013 Feb 14.

Classic Kaposi's sarcoma (CKS) is a subtype that traditionally occurs in elderly HIV-negative males of Mediterranean origin. Patients with CKS characteristically present with skin lesions in the distal extremities. Involvement of the viscera is uncommon but may occur in...

Cite
Benbrahim Z, Arifi S, Benhammane H, et al. Quasi-Complete Response of Classic Kaposi's Sarcoma Treated with Weekly Paclitaxel. Case Rep Oncol Med. 2013;2013:196878doi: 10.1155/2013/196878.
Benbrahim, Z., Arifi, S., Benhammane, H., Inani, K., Gallouj, S., Meziane, M., Mernissi, F. Z., Mellas, N., & El Mesbahi, O. (2013). Quasi-Complete Response of Classic Kaposi's Sarcoma Treated with Weekly Paclitaxel. Case reports in oncological medicine, 2013196878. https://doi.org/10.1155/2013/196878
Benbrahim, Zineb, et al. "Quasi-Complete Response of Classic Kaposi's Sarcoma Treated with Weekly Paclitaxel." Case reports in oncological medicine vol. 2013 (2013): 196878. doi: https://doi.org/10.1155/2013/196878
Benbrahim Z, Arifi S, Benhammane H, Inani K, Gallouj S, Meziane M, Mernissi FZ, Mellas N, El Mesbahi O. Quasi-Complete Response of Classic Kaposi's Sarcoma Treated with Weekly Paclitaxel. Case Rep Oncol Med. 2013;2013:196878. doi: 10.1155/2013/196878. Epub 2013 Feb 14. PMID: 23476845; PMCID: PMC3586472.
Copy Download .nbib Format: NLM
Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

OncoTargets and therapy

Chen D, Cheng J, Yang K, Ma Y, Yang F.
PMID: 24187501
Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013.

BACKGROUND: Chronomodulated chemotherapy has emerged as a new therapy as a result of recent studies focusing on the biological clock. It has been demonstrated that combination chronomodulated chemotherapy of platinum-based drugs and 5-fluorouracil (5-Fu) can significantly improve efficacy and...

Cite
Chen D, Cheng J, Yang K, et al. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013;6:1507-14doi: 10.2147/OTT.S53098.
Chen, D., Cheng, J., Yang, K., Ma, Y., & Yang, F. (2013). Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. OncoTargets and therapy, 61507-14. https://doi.org/10.2147/OTT.S53098
Chen, Dan, et al. "Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma." OncoTargets and therapy vol. 6 (2013): 1507-14. doi: https://doi.org/10.2147/OTT.S53098
Chen D, Cheng J, Yang K, Ma Y, Yang F. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013. PMID: 24187501; PMCID: PMC3810446.
Copy Download .nbib Format: NLM
Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel.

European journal of mass spectrometry (Chichester, England)

Traldi P, Calandra E, Crotti S, Agostini M, Nitti D, Roverso M, Toffoli G, Marangon E, Posocco B.
PMID: 25905869
Eur J Mass Spectrom (Chichester). 2014;20(6):445-59. doi: 10.1255/ejms.1302.

The development of surface-assisted laser desorption/ionization (SALDI) methodologies in mass spectrometry allows, in principle, the development of new analytical approaches to qualitative and quantitative measurements on small molecules. Some of these methods have been applied to characterize two antineoplastic...

Cite
Traldi P, Calandra E, Crotti S, et al. Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel. Eur J Mass Spectrom (Chichester). 2014;20(6):445-59doi: 10.1255/ejms.1302.
Traldi, P., Calandra, E., Crotti, S., Agostini, M., Nitti, D., Roverso, M., Toffoli, G., Marangon, E., & Posocco, B. (2014). Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel. European journal of mass spectrometry (Chichester, England), 20(6), 445-59. https://doi.org/10.1255/ejms.1302
Traldi, Pietro, et al. "Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel." European journal of mass spectrometry (Chichester, England) vol. 20,6 (2014): 445-59. doi: https://doi.org/10.1255/ejms.1302
Traldi P, Calandra E, Crotti S, Agostini M, Nitti D, Roverso M, Toffoli G, Marangon E, Posocco B. Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel. Eur J Mass Spectrom (Chichester). 2014;20(6):445-59. doi: 10.1255/ejms.1302. PMID: 25905869.
Copy Download .nbib Format: NLM
Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis.

Oncotarget

Yang L, Guo G, Sun L, Li C, Zhang H.
PMID: 28938689
Oncotarget. 2017 Mar 30;8(35):59867-59877. doi: 10.18632/oncotarget.16729. eCollection 2017 Aug 29.

BACKGROUND: Ovarian neoplasm is a kind of high risky cancer among female. This paper assessed the efficacy and safety of twelve therapies and figured out the superior chemotherapeutic drug for ovarian cancer through network meta-analysis (NMA).METHOD: Eligible randomized controlled...

Cite
Yang L, Guo G, Sun L, et al. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget. 2017;8(35):59867-59877doi: 10.18632/oncotarget.16729.
Yang, L., Guo, G., Sun, L., Li, C., & Zhang, H. (2017). Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget, 8(35), 59867-59877. https://doi.org/10.18632/oncotarget.16729
Yang, Lili, et al. "Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis." Oncotarget vol. 8,35 (2017): 59867-59877. doi: https://doi.org/10.18632/oncotarget.16729
Yang L, Guo G, Sun L, Li C, Zhang H. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget. 2017 Mar 30;8(35):59867-59877. doi: 10.18632/oncotarget.16729. eCollection 2017 Aug 29. PMID: 28938689; PMCID: PMC5601785.
Copy Download .nbib Format: NLM
Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative.

Cancer cell international

Reynisson J, Jaiswal JK, Barker D, D'mello SA, Denny WA, Baguley BC, Leung EY.
PMID: 26966420
Cancer Cell Int. 2016 Mar 10;16:18. doi: 10.1186/s12935-016-0293-6. eCollection 2016.

BACKGROUND: The thieno[2,3-b]pyridines were discovered by virtual high throughput screening as potential inhibitors of phospholipase C (PLC) isoforms and showed potent growth inhibitory effects in National Cancer Institute's human tumour cell line panel (NCI60). The mechanism of the anti-proliferative...

Cite
Reynisson J, Jaiswal JK, Barker D, et al. Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer Cell Int. 2016;16:18doi: 10.1186/s12935-016-0293-6.
Reynisson, J., Jaiswal, J. K., Barker, D., D'mello, S. A., Denny, W. A., Baguley, B. C., & Leung, E. Y. (2016). Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer cell international, 1618. https://doi.org/10.1186/s12935-016-0293-6
Reynisson, Jóhannes, et al. "Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative." Cancer cell international vol. 16 (2016): 18. doi: https://doi.org/10.1186/s12935-016-0293-6
Reynisson J, Jaiswal JK, Barker D, D'mello SA, Denny WA, Baguley BC, Leung EY. Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer Cell Int. 2016 Mar 10;16:18. doi: 10.1186/s12935-016-0293-6. eCollection 2016. PMID: 26966420; PMCID: PMC4785615.
Copy Download .nbib Format: NLM
Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report.

Surgical case reports

Aoyagi K, Kizaki J, Isobe T, Akagi Y.
PMID: 26943449
Surg Case Rep. 2015 Dec;1(1):125. doi: 10.1186/s40792-015-0126-1. Epub 2015 Dec 24.

A 69-year-old man was referred to our institution for treatment of gastric cancer. Type 2 gastric cancer was found on the anterior wall of the lower body of the stomach.The patient underwent distal gastrectomy, D2 lymph node dissection, and...

Cite
Aoyagi K, Kizaki J, Isobe T, et al. Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surg Case Rep. 2015;1(1):125doi: 10.1186/s40792-015-0126-1.
Aoyagi, K., Kizaki, J., Isobe, T., & Akagi, Y. (2015). Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surgical case reports, 1(1), 125. https://doi.org/10.1186/s40792-015-0126-1
Aoyagi, Keishiro, et al. "Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report." Surgical case reports vol. 1,1 (2015): 125. doi: https://doi.org/10.1186/s40792-015-0126-1
Aoyagi K, Kizaki J, Isobe T, Akagi Y. Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surg Case Rep. 2015 Dec;1(1):125. doi: 10.1186/s40792-015-0126-1. Epub 2015 Dec 24. PMID: 26943449; PMCID: PMC4690825.
Copy Download .nbib Format: NLM
Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles.

Oncotarget

Zou L, Wang D, Hu Y, Fu C, Li W, Dai L, Yang L, Zhang J.
PMID: 28947984
Oncotarget. 2017 Jul 31;8(36):60453-60468. doi: 10.18632/oncotarget.19728. eCollection 2017 Sep 01.

Paclitaxel (PTX) is frequently suffered from multidrug resistance (MDR), resulting in lower chemotherapeutic efficacy and even chemotherapy failure. To combine the P-glycolprotein (P-gp) inhibitor would be a useful strategy to overcome MDR. However, what is needed now is an...

Cite
Zou L, Wang D, Hu Y, et al. Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles. Oncotarget. 2017;8(36):60453-60468doi: 10.18632/oncotarget.19728.
Zou, L., Wang, D., Hu, Y., Fu, C., Li, W., Dai, L., Yang, L., & Zhang, J. (2017). Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles. Oncotarget, 8(36), 60453-60468. https://doi.org/10.18632/oncotarget.19728
Zou, Liang, et al. "Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles." Oncotarget vol. 8,36 (2017): 60453-60468. doi: https://doi.org/10.18632/oncotarget.19728
Zou L, Wang D, Hu Y, Fu C, Li W, Dai L, Yang L, Zhang J. Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles. Oncotarget. 2017 Jul 31;8(36):60453-60468. doi: 10.18632/oncotarget.19728. eCollection 2017 Sep 01. PMID: 28947984; PMCID: PMC5601152.
Copy Download .nbib Format: NLM
Double-Walled Microparticles-Embedded Self-Cross-Linked, Injectable, and Antibacterial Hydrogel for Controlled and Sustained Release of Chemotherapeutic Agents.

ACS applied materials & interfaces

Davoodi P, Ng WC, Yan WC, Srinivasan MP, Wang CH.
PMID: 27530316
ACS Appl Mater Interfaces. 2016 Sep 07;8(35):22785-800. doi: 10.1021/acsami.6b03041. Epub 2016 Aug 25.

First-line cancer chemotherapy has been prescribed for patients suffered from cancers for many years. However, conventional chemotherapy provides a high parenteral dosage of anticancer drugs over a short period, which may cause serious toxicities and detrimental side effects in...

Cite
Davoodi P, Ng WC, Yan WC, et al. Double-Walled Microparticles-Embedded Self-Cross-Linked, Injectable, and Antibacterial Hydrogel for Controlled and Sustained Release of Chemotherapeutic Agents. ACS Appl Mater Interfaces. 2016;8(35):22785-800doi: 10.1021/acsami.6b03041.
Davoodi, P., Ng, W. C., Yan, W. C., Srinivasan, M. P., & Wang, C. H. (2016). Double-Walled Microparticles-Embedded Self-Cross-Linked, Injectable, and Antibacterial Hydrogel for Controlled and Sustained Release of Chemotherapeutic Agents. ACS applied materials & interfaces, 8(35), 22785-800. https://doi.org/10.1021/acsami.6b03041
Davoodi, Pooya, et al. "Double-Walled Microparticles-Embedded Self-Cross-Linked, Injectable, and Antibacterial Hydrogel for Controlled and Sustained Release of Chemotherapeutic Agents." ACS applied materials & interfaces vol. 8,35 (2016): 22785-800. doi: https://doi.org/10.1021/acsami.6b03041
Davoodi P, Ng WC, Yan WC, Srinivasan MP, Wang CH. Double-Walled Microparticles-Embedded Self-Cross-Linked, Injectable, and Antibacterial Hydrogel for Controlled and Sustained Release of Chemotherapeutic Agents. ACS Appl Mater Interfaces. 2016 Sep 07;8(35):22785-800. doi: 10.1021/acsami.6b03041. Epub 2016 Aug 25. PMID: 27530316.
Copy Download .nbib Format: NLM
Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study.

Thoracic cancer

Ding ZY, Zhou L, Liu YM, Lu Y.
PMID: 28920321
Thorac Cancer. 2013 Feb;4(1):14-19. doi: 10.1111/j.1759-7714.2012.00134.x.

BACKGROUND:   Lung cancer in elderly patients poses an increasingly challenge for oncologists. The optimal treatment needs to be explored. The purpose of this study was to evaluate the safety and efficacy of the novel form of paclitaxel liposome for...

Cite
Ding ZY, Zhou L, Liu YM, et al. Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study. Thorac Cancer. 2013;4(1):14-19doi: 10.1111/j.1759-7714.2012.00134.x.
Ding, Z. Y., Zhou, L., Liu, Y. M., & Lu, Y. (2013). Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study. Thoracic cancer, 4(1), 14-19. https://doi.org/10.1111/j.1759-7714.2012.00134.x
Ding, Zhen-Yu, et al. "Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study." Thoracic cancer vol. 4,1 (2013): 14-19. doi: https://doi.org/10.1111/j.1759-7714.2012.00134.x
Ding ZY, Zhou L, Liu YM, Lu Y. Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study. Thorac Cancer. 2013 Feb;4(1):14-19. doi: 10.1111/j.1759-7714.2012.00134.x. PMID: 28920321.
Copy Download .nbib Format: NLM
A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells.

Oncology letters

Weng Y, Shi Y, Xia X, Zhou W, Wang H, Wang C.
PMID: 28454290
Oncol Lett. 2017 Mar;13(3):1553-1562. doi: 10.3892/ol.2017.5672. Epub 2017 Feb 02.

RNA interference (RNAi) is a powerful technology for suppressing gene function. In most studies, small interfering RNAs (siRNAs) consist of one short hairpin RNA (shRNA) and, therefore, are often unable to achieve loss-of-function of their target genes. In the...

Cite
Weng Y, Shi Y, Xia X, et al. A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells. Oncol Lett. 2017;13(3):1553-1562doi: 10.3892/ol.2017.5672.
Weng, Y., Shi, Y., Xia, X., Zhou, W., Wang, H., & Wang, C. (2017). A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells. Oncology letters, 13(3), 1553-1562. https://doi.org/10.3892/ol.2017.5672
Weng, Yanjie, et al. "A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells." Oncology letters vol. 13,3 (2017): 1553-1562. doi: https://doi.org/10.3892/ol.2017.5672
Weng Y, Shi Y, Xia X, Zhou W, Wang H, Wang C. A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells. Oncol Lett. 2017 Mar;13(3):1553-1562. doi: 10.3892/ol.2017.5672. Epub 2017 Feb 02. PMID: 28454290; PMCID: PMC5403481.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 4719 entries